CORE C: Clinical and Data Management Core (UC Berkeley, University of Michigan, Sustainable Sciences Institute) SUMMARY The Clinical and Data Management Core (Core C) will be instrumental for the success of the P01 Program. First, the Core will continue to conduct the Pediatric Dengue Cohort Study in Managua, Nicaragua. This cohort study is the longest continuous cohort study of dengue and as such is an invaluable source of samples and clinical data from children with natural repeat dengue virus (DENV) infections. Both retrospectively and prospectively collected samples and data will be available to the P01 Projects. Core C will oversee all aspects of running the Cohort Study including enrollment, sample collection and storage, data collection and management, quality control, provision of medical care, and human subjects documentation. Second, Core C will coordinate the compilation of clinical data and the distribution of samples available from the P01 Program dengue studies in Nicaragua and the Philippines, where a cohort study of children vaccinated with the Dengvaxia dengue vaccine is ongoing. To this end, the Core will design, maintain, update and oversee the P01 Program databases, which will include clinical data, sample characteristics and availability. Core C will provide tailored data sets and assist in selection of analysis-specific biological specimens, ensuring efficient data sharing and sample distribution through the implementation of high levels of quality control. This will include having a data manager at the University of Michigan (UM) who will compile the data from the clinical sites and use it to assemble data sets, including the creation of any necessary variables for P01 Program sites. Core C personnel at UC Berkeley will be responsible for receiving samples from Nicaragua, maintaining an inventory, and distributing the samples to P01 Projects in response to requests and in coordination with the data manager at UM. Third, the Core will maintain a copy of immunological data generated through the Projects 1-3 and Core B and will deposit data into ImmPort. P01 investigators will be able to submit data for upload to and download data from the database, facilitating the flow of information across all P01 Program partners.
Aim 1 is to continue conducting the community-based prospective Pediatric Dengue Cohort Study in Managua, Nicaragua.
Aim 2 is to coordinate clinical data compilation, integration and distribution, and shipment of clinical samples, and to perform phylogenetic sequencing.
Aim 3 is to manage data generated through the P01 and to deposit immunological data generated through the P01 Projects and Cores into ImmPort. Taken together, the Clinical and Data Management Core will play an essential role in the P01 Program by providing data and samples to scientific Projects for the ultimate purpose of identifying both natural and vaccine-induced immune correlates of protection against dengue disease.

Public Health Relevance

(CORE C) Dengue is a major health problem worldwide and is complicated by 4 distinct yet cross-reactive serotypes. This P01 addresses the critical need to improve understanding of human B and T cell responses to dengue virus infection and vaccination and identify immune correlates of protection from or susceptibility to disease. Core C will continue the Nicaraguan Pediatric Dengue Cohort Study to provide key samples from natural repeat dengue virus infections. It will also ensure efficient management and distribution of samples and data from the cohort and other human subject studies to Projects, collaborate on the selection of samples, and maintain P01 databases and the project workspace.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
2P01AI106695-06
Application #
9856091
Study Section
Special Emphasis Panel (ZAI1)
Project Start
2015-07-29
Project End
2025-07-31
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
6
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of California Berkeley
Department
Type
DUNS #
124726725
City
Berkeley
State
CA
Country
United States
Zip Code
94710
Balmaseda, Angel; Zambrana, José Victor; Collado, Damaris et al. (2018) Comparison of Four Serological Methods and Two Reverse Transcription-PCR Assays for Diagnosis and Surveillance of Zika Virus Infection. J Clin Microbiol 56:
Katzelnick, Leah C; Ben-Shachar, Rotem; Mercado, Juan Carlos et al. (2018) Dynamics and determinants of the force of infection of dengue virus from 1994 to 2015 in Managua, Nicaragua. Proc Natl Acad Sci U S A 115:10762-10767
Frei, Julia C; Wirchnianski, Ariel S; Govero, Jennifer et al. (2018) Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice. J Virol 92:
Mishra, Nischay; Caciula, Adrian; Price, Adam et al. (2018) Diagnosis of Zika Virus Infection by Peptide Array and Enzyme-Linked Immunosorbent Assay. MBio 9:
Thézé, Julien; Li, Tony; du Plessis, Louis et al. (2018) Genomic Epidemiology Reconstructs the Introduction and Spread of Zika Virus in Central America and Mexico. Cell Host Microbe 23:855-864.e7
Dhanda, Sandeep Kumar; Karosiene, Edita; Edwards, Lindy et al. (2018) Predicting HLA CD4 Immunogenicity in Human Populations. Front Immunol 9:1369
Patil, Veena S; Madrigal, Ariel; Schmiedel, Benjamin J et al. (2018) Precursors of human CD4+ cytotoxic T lymphocytes identified by single-cell transcriptome analysis. Sci Immunol 3:
Oldfield, Lauren M; Fedorova, Nadia; Puri, Vinita et al. (2018) Sequences of Zika Virus Genomes from a Pediatric Cohort in Nicaragua. Genome Announc 6:
Vannice, Kirsten S; Wilder-Smith, Annelies; Barrett, Alan D T et al. (2018) Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines. Vaccine 36:3411-3417
Rojas, Alejandra; Diagne, Cheikh T; Stittleburg, Victoria D et al. (2018) Internally Controlled, Multiplex Real-Time Reverse Transcription PCR for Dengue Virus and Yellow Fever Virus Detection. Am J Trop Med Hyg 98:1833-1836

Showing the most recent 10 out of 54 publications